The global pharmaceutical contract manufacturing and research services market size was estimated at USD 281.68 billion in 2025 and is predicted to increase from USD 301.23 billion in 2026 to approximately USD 551.01 billion by 2035, expanding at a CAGR of 6.94% from 2026 to 2035.
The growing advancement in drug discovery and development is increasing the use of pharmaceutical contract manufacturing and research services, where the increasing advanced therapies, AI integration, clinical trials, and new platform launches are also promoting the market growth.
The pharmaceutical contract manufacturing and research services market is driven by a growing shift towards end-to-end strategic collaboration, patent expiration, and increasing biologics. The pharmaceutical contract manufacturing and research services refer to the services provided to the pharmaceutical companies by specialized third-party companies. They offer a wide range of services supporting drug research, development, and manufacturing to the pharmaceutical companies.
Among these activities are drug discovery, preclinical research, clinical trial assistance, testing, formulation of drugs, large-scale production, packing, and regulatory support. Pharmaceutical companies now rely on contractors for trimming down their production costs, speed up product development process, and get access to technology and know-how. The growing need for biologics and custom-made medicines further propels the requirement for outsourcing. Additionally, rising investments in R&D, ever increasing number of drugs under development, and strict quality requirements are fostering long-term cooperation between pharmaceutical companies and contractors.
The impact of AI on the pharmaceutical contract manufacturing and research services market is increasing as it helps in accelerating drug discovery and development, promoting the development of optimized products. It also analyses large datasets, provides insights, and reduces the chances of product failure. Its automated data processing and enhanced quality control detect defects in the systems and promote the development of consistent quality products.
Flourishing Complex Treatment Options
The growing chronic disease burden globally is increasing the demand for cell & gene therapies, biologics, and biosimilars, which is increasing their development and innovations, driving the demand for pharmaceutical contract manufacturing and research services.
Expanding Outsourcing Trends
The growth in the R&D activities and production rates is increasing the outsourcing trends, leading to new collaborations for pharmaceutical contract manufacturing and research services, in order to focus on new drug candidates and reduce the cost associated with their development.
Blooming Technologies
To boost efficiency and applications with end-to-end solutions and continuous manufacturing, new CRO-CDMO hybrid models are being launched along with the integration of automation and new digital tools.
| Key Elements | Scope |
| Market Size in 2026 | USD 301.23 Billion |
| Projected Market Size in 2035 | USD 551.01 Billion |
| CAGR (2026 - 2035) | 6.94% |
| Leading Region | Asia Pacific by 45% |
| Historical Data | 2020 - 2023 |
| Base Year | 2025 |
| Forecast Period | 2026 - 2035 |
| Measurable Values | USD Millions/Units/Volume |
| Market Segmentation | By Service , By End-User, By Region |
| Top Key Players | Lonza Group, Thermo Fisher Scientific, Catalent, WuXi AppTec, IQVIA, Siegfried Holding, Boehringer Ingelheim, Recipharm, Samsung Biologics, Eurofins Scientific |
| Segments | Shares % |
| Manufacturing | 64% |
| Research | 36% |
Which Service Type Segment Held the Dominating Share of the Market in 2025?
The manufacturing segment held the dominating share of the pharmaceutical contract manufacturing and research services market by 64% share in 2025, due to continuous commercial-scale production. The growth in the demand for sophisticated equipment, GMP compliance, and expensive facilities increased the use of pharmaceutical contract manufacturing and research services. Advancements in biologics also increased their demand.
Research
The research segment is expected to show the highest growth during the upcoming years, due to growing drug discovery and development. Similarly, increasing innovations of gene therapies and biosimilars are also increasing the demand and use of pharmaceutical contract manufacturing and research services. The growing demand for specialized expertise and increasing outsourcing trends are also driving their acceptance rates.
| Segments | Shares % |
| Big Pharma | 46% |
| Small Pharma | 24% |
| Generic Pharma | 18% |
| Contract Research Organizations | 12% |
What Made Big Pharma the Dominant Segment in the Market in 2025?
The big pharma segment contributed the biggest revenue share of 46% of the pharmaceutical contract manufacturing and research services market in 2025, due to growth in the R&D activities and clinical pipeline. This increased the use of pharmaceutical contract manufacturing and research services for specialized expertise and regulatory compliance. Moreover, growth in the drug production rates also increased the collaborations to leverage these services.
Contract Research Organizations
The contract research organizations segment is expected to witness rapid growth during the predicted time, due to growing outsourcing trends. The increasing advancements in the discovery and development of new molecules are also increasing the demand for pharmaceutical contract manufacturing and research services, where their affordability, regulatory expertise, and advanced technologies are also increasing their use.
Asia Pacific dominated the pharmaceutical contract manufacturing and research services market share by 45% in 2025, due to the rapid expansion of pharmaceutical and biotechnology companies, which is increasing the development of new products, encouraging the use of pharmaceutical contract manufacturing and research services. Growing outsourcing trends, disease burden, and government support are also enhancing the market growth.
India Market Trends
The growth in the CRO and CDMO ecosystem in India is increasing their collaboration to accelerate the development of various drug products. The growth in the generic product development and increasing skilled personnel are also increasing the use of pharmaceutical contract manufacturing and research services, where their affordability and quality controls are also promoting the acceptance rates.
Japan Market Trends
The pharmaceutical contract manufacturing and research services market in Japan is being positively influenced by the a combination of innovative pharmaceutical research, high-quality manufacturing practices, and rise in the need for specialized outsourcing services. The ongoing progress of biologics, cell therapies, gene therapies, and precision medicines is motivating the pharmaceutical companies to team up with contract research and manufacturing organizations for improved efficiency.
China Market Trends
Pharmaceutical contract manufacturing and research services market has reached a leading position in China with rapidly emerging biopharmaceutical industries, high capacity manufacturing firms in the country, and government initiatives promoting pharmaceuticals innovations. Rising investments in clinical development activities, biologics manufacturing, and new technologies enable efficient production of drugs.
North America is estimated to be the fastest-growing region in the pharmaceutical contract manufacturing and research services market by 25% share during 2026-2035, due to growth in the R&D investments, which increased the R&D activities, driving the demand for pharmaceutical contract manufacturing and research services. The presence of well-developed pharmaceutical industries and startups also increased their use due to growing drug development advancements and clinical trials, which contributed to the market growth.
U.S. Market Trends
The U.S. consists of large pharmaceutical and biotech companies that are backed by R&D investment, which is accelerating drug discovery and development. Increasing demand for advanced therapies and personalized medication is also driving their innovations where stringent regulations are also increasing the use of pharmaceutical contract manufacturing and research services.
Canada Market Trends
The pharmaceutical contract manufacturing and research services market in Canada is continuously growing resulting from the increased biopharmaceutical research, an increase in clinical trials and increase in the need for drug development outsourcing. The existence of stringent regulations, enhanced manufacturing practices and government support in the life sciences innovation is allowing pharmaceutical and biotechnology industries to work with contract research organizations and contract development and manufacturing organizations.
Mexico Market Trends
The pharmaceutical contract manufacturing and research services market in the country of Mexico is growing as companies are looking for inexpensive options for manufacturing and clinical research purposes. The rising pharmaceutical production, availability of quality workforce and increase in foreign investments in Mexico is strengthening its position in terms of being a regional outsourcing destination. The rising demand for biologics and generics is further supporting the growth of the market.
Europe is expected to grow significantly in the pharmaceutical contract manufacturing and research services market by 18% share during the forecast period, due to the presence of advanced pharmaceutical industries, increasing the use of pharmaceutical contract manufacturing and research services due to growing drug development and innovations. Stringent regulations, growing clinical trials, and government investments are also promoting the market growth.
UK Market Trends
The presence of robust industries and R&D infrastructure in the UK is increasing the advancements in gene therapies, personalized medicines, and biologics, driving the demand for pharmaceutical contract manufacturing and research services. Growing clinical trials and government investments are also increasing their use, leading to new collaborations.
Germany market Trends
Pharmaceutical contract manufacturing and research services market is significantly developed in Germany owing to the well-established pharmaceutical industry, success of the innovative research ecosystem as well as active regulation of manufacturing processes. The globalization of the pharmaceutical manufacturing industry has been enabled by the outsourcing of drug manufacturing, clinical research activities, and commercial production processes.
Netherlands Market Trends
The pharmaceutical contract manufacturing and research services market in the Netherlands is growing steadily with a remarkable biotechnology sector, efficient infrastructure firms, and high-quality research institutes in the country. This has led to a growing demand for biologics manufacturing, clinical research, and specific types of manufacturing services.
The Latin America pharmaceutical contract manufacturing and research services market size stood at US$ 22.53 billion in 2025, grew to US$ 24.09 billion in 2026, and is forecast to reach US$ 43.99 billion by 2035, expanding at a CAGR of 6.92% from 2026 to 2035.
R&D
Clinical Trials and Regulatory Approvals
Packaging and Serialization
Patient Support and Services
| Companies | Headquarters | Pharmaceutical Contract Manufacturing and Research Services |
| Lonza Group | Basel, Switzerland | Services for biologics, small molecule API and cell and gene therapies |
| Thermo Fisher Scientific | Waltham, U.S. | End-to-end solutions from drug substance manufacturing to commercial packaging and clinical research |
| Catalent | Somerset, U.S. | Offer advanced drug delivery technologies, sterile injectables, and oral dose formulation. |
| WuXi AppTec | Shanghai, China | Comprehensive “CRDMO” services, such as discovery chemistry, small molecule manufacturing, and preclinical research |
| IQVIA | Durham, U.S. | Extensive clinical trial management, data analytics, and commercialization services |
| Siegfried Holding | Zofingen, Switzerland | Drug substance and drug product manufacturing |
| Boehringer Ingelheim | Ingelheim, Germany | Process development to fill and finish services for biopharmaceuticals |
| Recipharm | Stockholm, Sweden | Manufacturing services for various dosage forms |
| Samsung Biologics | Incheon, South Korea | Large biopharmaceutical manufacturing services for mRNA and monoclonal antibody products |
| Eurofins Scientific | Luxembourg City, Luxembourg | Integrated drug discovery, development, and analytical testing services |
Strengths
Weaknesses
Opportunities
Threats
In May 2026, Wacker launched contract research services for nucleic acid-based therapies, providing R&D-grade plasmid DNA, RNA, and lipid nanoparticle solutions to accelerate drug development. Christian Dubiella, CRS Global Program Manager, said, “Every RNA or LNP project is unique. Our goal is to provide flexible, customizable services that adapt to our clients’ specific needs in a rapidly evolving landscape.”
In March 2026, Forma Life Sciences launched a U.S.-based CDMO focused on oral solid dosage development and commercial manufacturing in Irvine, California. Executive Chairman and CEO Cyrus Mirsaidi stated, “Forma was created to preserve that operating foundation while building a focused U.S. based CDMO platform designed for disciplined execution and long-term partnership.”
In May 2026, FUJIFILM Cellular Dynamics opened a new iPSC manufacturing facility and headquarters in Madison, Wisconsin, significantly expanding production capacity for regenerative medicine and cell therapy. Chief Operating Officer Delara Motlagh said, “This investment speaks to the heart of innovation that happens in Madison - all the incredibly talented researchers and innovators.”
By Service
By End-User
By Region
Principal Consultant
Rohan Patil is a seasoned market research professional with over 5+ years of focused experience in the healthcare sector, bringing deep domain expertise, strategic foresight, and analytical precision to every project he undertakes.
Learn more about Rohan Patil
Reviewed By
Aditi Shivarkar is a seasoned professional with over 14 years of experience in healthcare market research. As a content reviewer, Aditi ensures the quality and accuracy of all market insights and data presented by the research team.
Learn more about Aditi Shivarkar
+1 804-441-9344
